AAA
VRDN icon

Affinity Asset Advisors’s Viridian Therapeutics VRDN Stock Holding History

Affinity Asset Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-130,400
Closed -$3.1M – 93
2023
Q2 		$3.1M Buy
130,400
+29,900
+30% +$767K 1.08% 30
2023
Q1 		$2.56M Buy
+100,500
New +$3.22M 0.84% 33

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Affinity Asset Advisors's VRDN Position: Q1 2026 in Review

Affinity Asset Advisors held its Viridian Therapeutics (VRDN) position steady in Q1 2026 at 250,000 shares worth $4.89M. The position accounts for 0.25% of the portfolio, ranked #69.

Affinity Asset Advisors first reported a position in VRDN in Q1 2022 and has held it in 11 quarters since. The position peaked at $11.9M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Affinity Asset Advisors held 250,000 shares of Viridian Therapeutics worth $4.89M as of Q1 2026.
  • Affinity Asset Advisors left its Viridian Therapeutics share count unchanged in Q1 2026.
  • Viridian Therapeutics made up 0.25% of Affinity Asset Advisors's portfolio in Q1 2026, its #69 holding.
  • Affinity Asset Advisors first reported a position in Viridian Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Affinity Asset Advisors's Viridian Therapeutics position peaked at $11.9M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.